ImmunityBio has secured a critical regulatory milestone for its lead oncology drug, Anktiva, providing a significant counterpoint to recent market volatility. An independent data monitoring board has concluded that the pivotal clinical trial is statistically powered to meet its objectives, clearing the path for a future regulatory submission.

Trial Meets Statistical Threshold, Enrollment Halted

The Independent Data Monitoring Committee (IDMC) conducted an interim analysis of the QUILT-2.005 Pivot study on March 26. Its review determined the trial possesses sufficient statistical power to demonstrate meaningful differences in response rates between the treatment arms. Having evaluated data from 183 assessable patients, the committee recommended halting further recruitment. The study, which has already enrolled 366 participants, is now considered complete.

This Phase 2/3 investigation is evaluating a combination of Anktiva and BCG immunotherapy versus BCG alone for patients with BCG-naïve non-muscle invasive bladder cancer. Based on the final data analysis, ImmunityBio intends to file a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration in the fourth quarter of 2026.

Strong Fundamentals Offset Recent Regulatory Scrutiny

The positive clinical update follows a difficult week for the company's share price. Just two days prior to the IDMC announcement, the FDA issued a warning letter concerning misleading promotional materials. The agency cited a television advertisement and a podcast where company representatives allegedly characterized Anktiva as a potential therapy for "all cancers" and a preventive agent. Anktiva is currently approved only for a specific form of bladder cancer. In response, ImmunityBio has initiated a legal and regulatory review to address the concerns within the mandated 15-day period. The news triggered a sell-off, with shares plunging over 20% to close at approximately $7.42.

Despite this short-term setback, the company's underlying financial and operational progress remains robust. For fiscal year 2025, ImmunityBio reported net product revenue of $113 million—a staggering 700% increase over the prior year. Market analysts project revenue will grow an additional 77% in 2026, reaching an estimated $195 million. Even after the recent decline, the equity has still advanced roughly 273% since the start of the year.

In a parallel development, the company successfully completed its NK2022 and NK2023 manufacturing runs for the M-ceNK cell therapy platform in March. The process is designed to yield up to five billion activated natural killer cells from a single apheresis cycle, theoretically producing enough material for eight to ten doses within a twelve-day production window. The planned sBLA submission at the end of 2026 will serve as a key test for the platform's commercial scalability.

Ad

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.